X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs J.B.CHEMICALS - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS J.B.CHEMICALS IPCA LABS/
J.B.CHEMICALS
 
P/E (TTM) x 28.1 17.1 163.9% View Chart
P/BV x 3.3 2.3 143.6% View Chart
Dividend Yield % 0.1 0.2 84.3%  

Financials

 IPCA LABS   J.B.CHEMICALS
EQUITY SHARE DATA
    IPCA LABS
Mar-18
J.B.CHEMICALS
Mar-16
IPCA LABS/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs695318 218.6%   
Low Rs400200 200.5%   
Sales per share (Unadj.) Rs260.2148.0 175.8%  
Earnings per share (Unadj.) Rs19.019.1 99.4%  
Cash flow per share (Unadj.) Rs33.123.9 138.0%  
Dividends per share (Unadj.) Rs1.000.50 200.0%  
Dividend yield (eoy) %0.20.2 94.5%  
Book value per share (Unadj.) Rs213.0128.9 165.2%  
Shares outstanding (eoy) m126.2084.82 148.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.11.7 120.4%   
Avg P/E ratio x28.913.6 212.9%  
P/CF ratio (eoy) x16.610.8 153.3%  
Price / Book Value ratio x2.62.0 128.1%  
Dividend payout %5.32.6 201.2%   
Avg Mkt Cap Rs m69,12021,951 314.9%   
No. of employees `00013.32.7 484.8%   
Total wages/salary Rs m7,3591,841 399.7%   
Avg. sales/employee Rs Th2,477.44,590.9 54.0%   
Avg. wages/employee Rs Th555.2673.4 82.4%   
Avg. net profit/employee Rs Th180.6592.1 30.5%   
INCOME DATA
Net Sales Rs m32,83612,551 261.6%  
Other income Rs m418542 77.2%   
Total revenues Rs m33,25413,093 254.0%   
Gross profit Rs m4,5052,055 219.2%  
Depreciation Rs m1,777412 431.0%   
Interest Rs m24096 251.0%   
Profit before tax Rs m2,9052,088 139.1%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511469 109.0%   
Profit after tax Rs m2,3941,619 147.9%  
Gross profit margin %13.716.4 83.8%  
Effective tax rate %17.622.5 78.3%   
Net profit margin %7.312.9 56.5%  
BALANCE SHEET DATA
Current assets Rs m19,4557,778 250.1%   
Current liabilities Rs m10,0764,358 231.2%   
Net working cap to sales %28.627.2 104.8%  
Current ratio x1.91.8 108.2%  
Inventory Days Days9855 179.1%  
Debtors Days Days6780 83.7%  
Net fixed assets Rs m20,2605,713 354.6%   
Share capital Rs m252170 148.8%   
"Free" reserves Rs m26,63310,547 252.5%   
Net worth Rs m26,88610,937 245.8%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17315,574 264.4%  
Interest coverage x13.122.8 57.4%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.8 99.0%   
Return on assets %6.411.0 58.1%  
Return on equity %8.914.8 60.2%  
Return on capital %10.820.0 53.9%  
Exports to sales %47.648.7 97.8%   
Imports to sales %14.97.1 210.1%   
Exports (fob) Rs m15,6426,115 255.8%   
Imports (cif) Rs m4,884889 549.5%   
Fx inflow Rs m15,6426,169 253.6%   
Fx outflow Rs m4,8841,285 380.0%   
Net fx Rs m10,7594,884 220.3%   
CASH FLOW
From Operations Rs m3,4111,397 244.2%  
From Investments Rs m-1,354-320 422.7%  
From Financial Activity Rs m-1,304-1,196 109.1%  
Net Cashflow Rs m753-102 -736.3%  

Share Holding

Indian Promoters % 45.9 55.4 82.9%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 11.4 3.4 336.3%  
FIIs % 25.3 3.9 648.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 37.0 47.0%  
Shareholders   36,892 30,437 121.2%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 21, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS